Company Market Research Report: Tissue Repair Ltd
Company Overview
Name, Mission of the Company
Name: Tissue Repair Ltd
Mission: Tissue Repair Ltd is committed to developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures with the potential for further development of related technologies.
Formation and Founders
Founded in: 2012
Founders: The company and its wholly owned US subsidiary, TR Therapeutics, Inc., were established to acquire the advanced wound care assets, intellectual property, and technology of Novogen Research Pty Ltd and Glycotex, Inc.
Key People in the Company
- Dr. Darryl Reed: Chief Operations Officer
- Tony Charara: Co-Founder and Executive Director
- Dr. Pramod Nednoor: Vice President of Chemistry and Controls
- William Bost: Vice President Manufacturing
- Cameron Jones: Chief Financial Officer
Headquarters
Location: Level 10, 255 Pitt St, Sydney, NSW, 2000, Australia
Number of Employees
Employees: 11-50
Revenue of the Company
Revenue: No information is available
Known For
Known for: Developing advanced wound healing products and a unique active ingredient for wound healing that simulates a yeast infection, thereby stimulating the body’s own wound repair pathways.
Products
Offered Products
- TR-987: Chronic wound treatment drug candidate.
- TR Pro+: A cosmeceutical post-procedure gel for use after minimally invasive cosmetic procedures.
High Level Description of Products
- TR-987: A biologically active pharmaceutical designed to treat chronic wounds by behaving like a decoy cell, stimulating body’s wound repair pathways.
- TR Pro+: A hydrogel used post-cosmetic procedures to soothe, rejuvenate, and protect the skin.
Key Features of Products
- TR-987
- Active Ingredient: Glucoprime, a high molecular weight, micro-particulate glucan.
- Designed for trophic ulcer repair
- Demonstrates safety and efficacy for ulcer healing.
- Planning to commence Phase III trials in 2024.
- TR Pro+
- Active Ingredient: Proprietary β-glucan Glucoprime® technology.
- Applied post-cosmetic procedures like needling and laser treatments.
- Protects against microbial infection.
- Provides intense nourishment and a cooling effect.
- Prevents transepidermal water loss.
- Approved as a TGA Listed Medicine.
Recent Developments
Recent Company Developments
- Funding and Clinical Trials:
- Raised $7.5m in May 2021 to progress business development and preparations for Phase III clinical trials.
- Planning to commence pivotal Phase III trials for TR-987 in 2024.
New Products Launched
- TR Pro+: Launched in the Australian market in 2022.
New Features Added
- TR Pro+ Hydrogel:
- Enhanced post-procedure skin protection.
- Effective for a broad range of cosmetic procedures.
Partnerships
- Contract Manufacturing: Partnered with a contract manufacturer to develop and manufacture the API for Phase III clinical use and beyond.
- Analytical Characterization: Partnership with a USA laboratory for further analytical characterization needed for Phase III trials.
Additional Developments
- Patent Approvals: Several patents granted in 2023 and 2024.
- Market Research: Conducted preliminary market research and business planning for TR Pro+.
This report contains detailed recent developments and focuses on the company’s mission, technology, products, and strategic position in the biopharmaceutical industry.
Note:
Revenue Information: No information is available
Other Financial Metrics: No additional financial metrics available
This comprehensive report aims to provide an overview and deep insights into Tissue Repair Ltd.’s current market landscape and position.
For more detailed inquiries, contact:
Darryl Reed
Chief Operating Officer
Email: darryl.reed@trtherapeutics.com
